1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Generics Industry Hungry For More After Showing Larger GLP-1 Appetite In 2024

Sandoz, Viatris Look To Be In Commercial Vanguard; Supply Core, CDMOs Vital

 
• By Dean Rudge

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.

Generics producers are keen for a piece of the GLP-1 pie

With the addition of weight loss and obesity indications and more patient-friendly dosing regimens beginning at the start of the current decade, glucagon-like-peptide-1 (GLP-1) receptor agonists have exploded into a multi-billion-dollar, cultural phenomenon, comparable in the prescription pharma space to the arrival of Viagra (sildenafil) in the late 1990s or Botox (onabotulinumtoxinA) before it.

The global market for such products has been tipped to reach $71bn by 2032, or even as high as $100bn by some estimates – and generics developers and manufacturers have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By Dean Rudge

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By Dean Rudge

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Abiogen And mAbxience Join Forces In Italy

 
• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.

Krka Looks To Kick On In India And China

 
• By Dean Rudge

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

More from Generics Bulletin Perspectives

Biosimilar Year In Review: Regulatory Achievements And Future Aspirations

 
• By Urtė Fultinavičiūtė

This year, regulators questioned the US interchangeability designation and the need for comparative efficacy trials, while finding ways to promote biosimilar development and accessibility. Will this momentum continue in 2025? Generics Bulletin spoke to experts from across the industry to hear their views.

The Generics Bulletin Podcast: Highlights Of 2024

 
• By Dave Wallace

Generics Bulletin's editorial team discusses key topics from the year, including the latest rankings of the Generics Bulletin Top 50, Amgen’s surprise launch of a US Eylea biosimilar, the EU’s Urban Waste Water Treatment Directive and supply-chain issues for the off-patent sector.

October Surprise: How Amgen’s Aflibercept Launch Shook Up US Biosimilars In 2024

 
• By Dave Wallace

As the US biosimilars market approaches the end of its first decade, it has seen another busy year, with Amgen’s surprise launch of a rival to Eylea shaking up expectations as other first-time approvals rolled in throughout 2024.